Triple agonist (GLP-1/GIP/glucagon) for significant weight loss (up to ~22-24% in trials at higher
doses), comprehensive metabolic improvements (reduced waist, BP, glucose, HbA1c),
substantial liver fat reduction (often >80% in NAFLD, with normalization in many), appetite
suppression + increased energy expenditure, muscle-sparing potential, and better
cardiovascular/liver risk factors.
$70.00
